Trial Profile
An Open-label, Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2022
Price :
$35
*
At a glance
- Drugs GZ 402668 (Primary) ; GZ 402668 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Sanofi Genzyme
- 22 Apr 2022 Status changed from active, no longer recruiting to completed.
- 20 Dec 2019 Planned End Date changed from 27 Apr 2022 to 1 Apr 2022.
- 20 Dec 2019 Planned primary completion date changed from 27 Apr 2022 to 1 Apr 2022.